UB407
TargetsWFS1
IndicationsSolid tumour
ClinicalCN - Pre-PCC
TherapeuticsOncology
ModalitiesSmall Molecule
Exclusive Summary
- • Potential FIC, A clinically unvalidated target, with no clinical competitors yet.
- • Significantly superior in vitro and in vivo anti-tumor efficacy comapre with M3913.
- • Favorable PK and safety profile in pre-clinical studies.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →